Botulinum Toxin-A for Painful Diabetic Neuropathy: A Meta-Analysis

Pain Medicine (United States)

Volumn 16, Issue 9, 2015, Pages 1773-1780

  Lakhan, Shaheen E ^a   Velasco, Dominic N ^a   Tepper, Deborah ^b  

^a Global Neuroscience Initiative Foundation   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Botulinum toxin; Diabetes; Neuropathic pain; Neuropathy; Visual analogue scale

Indexed keywords

BOTULINUM TOXIN A; PLACEBO; MUSCLE RELAXANT AGENT;

AGE; ANALGESIC ACTIVITY; ARTICLE; COMORBIDITY; DIABETIC NEUROPATHY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ETHNICITY; GENDER; HUMAN; INJECTION SITE INFECTION; META ANALYSIS (TOPIC); NEUROPATHIC PAIN; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PAINFUL DIABETIC NEUROPATHY; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); SLEEP QUALITY; SYSTEMATIC REVIEW; VISUAL ANALOG SCALE; DIABETIC NEUROPATHIES; DOUBLE BLIND PROCEDURE; META ANALYSIS; NEURALGIA;

BOTULINUM TOXINS, TYPE A; DIABETIC NEUROPATHIES; DOUBLE-BLIND METHOD; HUMANS; NEURALGIA; NEUROMUSCULAR AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84941731875     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/pme.12728     Document Type: Article

References (32)

1. Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. Atlanta, GA: U.S. Department of Health and Human Services; 2014.
2. Partanen J, Niskanen L, Lehtinen J, et al. Natural history of peripheral neuropathy in patients with non-insulin dependent diabetes. N Engl J Med 1995;333:89-94.
3. Abbott CA, Malik RA, van Ross ER, Kulkami J, Boulton AJ. Prevalence and chracteristics of painful diabetic neuropathy in a large community-based diabetic population in the UK. Diabetes Care 2011;43:2220-4.
4. Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care 2006;29:1518-1522.
5. Treede RD, Jensen TS, Campbell JN, et al. Neuropathic pain: Redefinition and a grading system for clinical research purposes. Neurology 2008;70(18):1630-5.
6. Oster G, Harding G, Dukes E, Edelsberg J, Cleary PD. Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: Results from a population-based survey. J Pain 2005;6(6):356-63.
7. Gore M, Brandenburg NA, Hoffman DL, Tai KS, Stacey B. Burden of illness in painful diabetic peripheral neuropathy: The patients' perspectives. J Pain 2006;7(12):892-900.
8. McDermott AM, Toelle TR, Rowbotham DJ, Schaefer CP, Dukes EM. The burden of neuropathic pain: Results of a cross-sectional survey. Eur J Pain 2006;10(2):127-135.
9. Jensen MP, Chodroff MJ, Dworkin RH. The impact of neuropathic pain on health-related quality of life: Review and implications. Neurology 2007;68(15):1178-82.
10. Sadosky A, Schaefer C, Mann R, et al. Burden of illness associated with painful diabetic peripheral neuropathy among adults seeking treatment in the US: Results from a retrospective chart review and cross-sectional survey. Diabetes Metab Syndr Obes 2013;6:79-92.
11. Berger A, Dukes EM, Oster G. Clinical characteristics and economic costs of patients with painful neuropathic disorders. J Pain 2004;5(3):143-9.
12. Callaghan BC, Cheng HT, Stables CL, et al. Diabetic neuropathy: Clinical manifestation and current treatments. Lancet Neurol 2012;11:521.
13. Edwards JL, Vincent AM, Cheng HT, Feldman EL. Diabetic neuropathy: Mechanisms to management. Pharmacol Ther 2008;120:1.
14. Pavone F, Luvisetto S. Botulinum neurotoxin for pain management: Insights from animal models. Toxins 2010;2:2890-2913.
15. Francisco G, Tan H, Green M. Do botulinum toxins have a role in the management of neuropathic pain? A focused review. Am J Phys Med Rehabil 2012;91(10):899-909.
16. Qerama E, Fuglsang-Frederiksen A, Jensen T. The role of botulinum toxin in management of pain: An evidence based review. Curr Opin Anaesthesiol 2010;23:602-610.
17. Jeynes LC, Gauci CA. Evidence for the use of botulinum toxin in the chronic pain setting: A review of the literature. Pain Practice 2008;8:269-276.
18. Aoki KR. Future aspects of botulinum neurotoxins. J Neural Transm 2008;115:567-573.
19. French J, Gronseth G. Lost in a jungle of evidence: We need a compass. Neurology 2008;71:1634-8.
20. Higgins JPT, Altman DG, Sterne JAC, Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). Oxford, England: The Cochrane Collaboration; 2011. Available at: http://community.cochrane.org/handbook.
21. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions, version 5.1.0, Updated March 2011. Chichester, England: Wiley; 2011.
22. Follmann D, Elliott P, Suh I, Cutler J. Variance imputation for overviews of clinical trials with continuous response. J Clin Epidemiol. 1992;45(7):769-73.
23. Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen, Oxford, England: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. Available at: http://tech.cochrane.org/revman.
24. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphicaltest. BMJ 1997;315(7109):629-34.
25. Yuan RY, Sheu JJ, Yu JM, et al. Botulinum toxin for diabetic neuropathic pain: A randomized double-blind crossover trial. Neurology 2009;72(17):1473-8.
26. Ghasemi M, Ansari M, Basiri K, et al. The effects of intradermal botulinum toxin type a injections on pain symptoms of patients with diabetic neuropathy. J Res Med Sci. 2014;19(2):106-11.
27. Chen WT, Yuan RY, Chiang SC, et al. OnabotulinumtoxinA improves tactile and mechanical pain perception in painful diabetic polyneuropathy. Clin J Pain 2013;29(4):305-10.
28. Bird SB, Dickson EW. Clinically significant changes in pain along the visual analog scale. Ann Emerg Med. 2001;38(6):639-643.
29. Gallagher EJ, Liebman M, Bijur PE. Prospective validation of clinically important changes in pain severity measured on a visual analog scale. Ann Emerg Med 2001;38:633-8.
30. Salaffi F, Stancati A, Silvestri CA, et al. Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scale. Eur J Pain 2004;8(4):283-91.
31. Jensen MP, Chen C, Brugger AM. Interpretation of visual analog scale ratings and change scores: A reanalysis of two clinical trials of postoperative pain. J Pain 2003;4(7):407-414.
32. Dworkin RH, O'Connor AB, Audette J, et al. Recommendations for the Pharmacological Management of Neuropathic Pain: An overview and literature update. Mayo Clin Proc 2010;85(3)(suppl):S3-14.